IART

Company Overview — What Does INTEGRA LIFESCIENCES HOLDINGS CORP Do?

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Jan D. de Witte and employs approximately 3,720 people, headquartered in Plainsboro, New Jersey. With a market capitalization of $746M, IART is one of the notable companies in the Healthcare sector.

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Stock Rating — Reduce (April 2026)

As of April 2026, INTEGRA LIFESCIENCES HOLDINGS CORP receives a Reduce rating with a composite score of 30.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IART ranks #3,732 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, INTEGRA LIFESCIENCES HOLDINGS CORP ranks #625 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IART Stock Price and 52-Week Range

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) currently trades at $9.90. The stock gained $0.07 (0.7%) in the most recent trading session. The 52-week high for IART is $23.16, which means the stock is currently trading -57.3% from its annual peak. The 52-week low is $8.76, putting the stock 13.0% above its annual trough. Recent trading volume was 486K shares, suggesting relatively thin trading activity.

Is IART Overvalued or Undervalued? — Valuation Analysis

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.70x, versus the sector average of 2.75x. The price-to-sales ratio is 0.46x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, IART trades at 31.57x EV/EBITDA, versus 6.34x for the sector.

At current multiples, INTEGRA LIFESCIENCES HOLDINGS CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

INTEGRA LIFESCIENCES HOLDINGS CORP Profitability — ROE, Margins, and Quality Score

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) earns a quality factor score of 39/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -50.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -14.6% versus the sector average of -33.1%.

On a margin basis, INTEGRA LIFESCIENCES HOLDINGS CORP reports gross margins of 51.3%, compared to 71.5% for the sector. The operating margin is -31.7% (sector: -66.1%). Net profit margin stands at -31.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -3.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IART Debt, Balance Sheet, and Financial Health

INTEGRA LIFESCIENCES HOLDINGS CORP has a debt-to-equity ratio of 70.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.54x, indicating strong short-term liquidity. Total debt on the balance sheet is $727M. Cash and equivalents stand at $232M.

IART has a beta of 1.46, meaning it is more volatile than the broader market — a $10,000 investment in IART would be expected to move 46.2% more than the S&P 500 on any given day. The stability factor score for INTEGRA LIFESCIENCES HOLDINGS CORP is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

INTEGRA LIFESCIENCES HOLDINGS CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $1.58B and earnings per share (EPS) of $-6.74. Net income for the quarter was $-525M. Gross margin was 51.3%. Operating income came in at $-525M.

In FY 2025, INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $1.64B and earnings per share (EPS) of $-6.74. Net income for the quarter was $-516M. Gross margin was 50.9%. Revenue grew 1.5% year-over-year compared to FY 2024. Operating income came in at $-493M.

In Q3 2025, INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $402M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-5M. Gross margin was 51.5%. Revenue grew 5.6% year-over-year compared to Q3 2024. Operating income came in at $12M.

In Q2 2025, INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $416M and earnings per share (EPS) of $-6.31. Net income for the quarter was $-484M. Gross margin was 50.4%. Revenue grew -0.6% year-over-year compared to Q2 2024. Operating income came in at $-513M.

Over the past 8 quarters, INTEGRA LIFESCIENCES HOLDINGS CORP has demonstrated a growth trajectory, with revenue expanding from $418M to $1.58B. Investors analyzing IART stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IART Dividend Yield and Income Analysis

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IART Momentum and Technical Analysis Profile

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

IART vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, INTEGRA LIFESCIENCES HOLDINGS CORP (IART) ranks #625 out of 838 stocks based on the Blank Capital composite score. This places IART in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IART against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IART vs S&P 500 (SPY) comparison to assess how INTEGRA LIFESCIENCES HOLDINGS CORP stacks up against the broader market across all factor dimensions.

IART Next Earnings Date

No upcoming earnings date has been announced for INTEGRA LIFESCIENCES HOLDINGS CORP (IART) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IART? — Investment Thesis Summary

The quantitative profile for INTEGRA LIFESCIENCES HOLDINGS CORP suggests caution. The quality score of 39/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 38/100) increases portfolio risk.

In summary, INTEGRA LIFESCIENCES HOLDINGS CORP (IART) earns a Reduce rating with a composite score of 30.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IART stock.

Related Resources for IART Investors

Explore more research and tools: IART vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IART head-to-head with peers: IART vs AZN, IART vs SLGL, IART vs VMD.